Olink Holding AB (OLK)
23.01
-0.01
(-0.04%)
USD |
NASDAQ |
May 03, 16:00
22.99
-0.02
(-0.09%)
After-Hours: 20:00
Olink Cash from Investing (TTM): -22.43M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -22.43M |
| September 30, 2023 | -15.49M |
| June 30, 2023 | -11.14M |
| March 31, 2023 | -9.126M |
| December 31, 2022 | -8.713M |
| September 30, 2022 | -11.80M |
| June 30, 2022 | -14.72M |
| Date | Value |
|---|---|
| March 31, 2022 | -16.43M |
| December 31, 2021 | -14.96M |
| September 30, 2021 | -11.54M |
| June 30, 2021 | -10.66M |
| March 31, 2021 | -16.16M |
| December 31, 2020 | -15.84M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-22.43M
Minimum
Dec 2023
-8.713M
Maximum
Dec 2022
-13.77M
Average
-14.72M
Median
Jun 2022
Cash from Investing (TTM) Benchmarks
| Thermo Fisher Scientific Inc | -4.03B |
| Abliva AB | -0.1218M |
| Karolinska Development AB | -3.475M |
| Calliditas Therapeutics AB | -- |
| Oncopeptides AB | -0.2606M |